Read by QxMD icon Read

Ovarian angiosarcoma

Surapan Khunamornpong, Jongkolnee Settakorn, Kornkanok Sukpan, Tip Pongsuvareeyakul, Sumalee Siriaunkgul
Angiosarcoma of the ovary is rare but represents an aggressive type of malignant ovarian neoplasms. The purpose of this report is to describe the features of angiosarcoma arising in mucinous tumor that was misinterpreted as a benign vascular proliferation during the intraoperative consultation. A 45-year-old woman presented with an abdominal mass for 1 month. Exploratory laparotomy was performed. A 35 cm right ovarian mass submitted for intraoperative consultation was a multicystic mucinous tumor with an 8 cm area of hemorrhagic lesion between cystic locules...
2016: Case Reports in Pathology
M M Al-Sanea, A Z Abdelazem, B S Park, K H Yoo, T Sim, Y J Kwon, S H Lee
ROS1 is a pivotal transmembrane receptor protein tyrosine kinase which regulates several cellular processes like apoptosis, survival, differentiation, proliferation, cell migration, and transformation. There is increasing evidence supporting that ROS1 plays an important role in different malignancies including glioblastoma, colorectal cancer, gastric adenocarcinoma, inflammatory myofibroblastic tumor, ovarian cancer, angiosarcoma, and non small cell lung cancer; thus, ROS1 has become a potential drug discovery target...
2016: Current Medicinal Chemistry
I Yonezawa, M Waki, Y Tamura, R Onoda, M Narushima, T Ishizuka, S Tajima
Angiosarcoma is a rare and aggressive type of sarcoma, and primary angiosarcoma of the ovary is extremely rare. We report the case of a 29-year-old woman who was diagnosed with ovarian angiosarcoma and possible bone metastases. We treated this patient with a gemcitabine-based regimen as postoperative adjuvant chemotherapy, after which she achieved at least 7 years of progression-free survival, an extremely long duration given the aggressive features of this tumour. We retrospectively performed immunohistochemical analyses and fluorescence in situ hybridization to make a pathology diagnosis and to investigate the tumour features...
December 2014: Current Oncology
P C Wu, C T Yue, S C Huang
The patient presented in this case report was a 45-year-old female, with a Stage IIIA ovarian angiosarcoma combined with mature teratoma, that underwent debulking surgery and achieved complete remission for 11 months after six cycles of MAID chemotherapy (mesna, adriamycin/doxorubicin, ifosfamide, and dacarbazine). Thereafter, she had tumor recurrence with peritoneal seeding and massive pleural effusion; hence she received chemotherapy again. Although she had been undergoing a series of chemotherapies, the tumor continued to progress...
2014: European Journal of Gynaecological Oncology
Rafael Dezen Gaiolla, Ivison Xavier Duarte, Carlos Eduardo Bacchi, Carlos Eduardo Paiva
Angiosarcomas are rare aggressive neoplasms of vascular endothelial origin with a high metastatic rate and poor prognosis. Involvement of the bone marrow by the angiosarcoma is exceedingly uncommon, and there have only been a few cases reported in the literature to date. Clinical manifestations and common laboratory findings of bone marrow involvement can mimic other more common bone marrow-replacing neoplasias such as lymphomas and acute leukemia. A definitive diagnosis is difficult to make from cytologic material, probably due to an associated bone marrow fibrosis, and requires bone marrow trephine biopsy with an immunohistochemical profile...
January 2014: Case Reports in Oncology
Nausheen Yaqoob, Dalal Nemenqani, Hatem Khoja, Moemen Hafez, Asma Tulbah, Fuoad Al-Dayel
INTRODUCTION: Sarcomas of the ovary can either be histologically pure or can represent components of a more complex tumor. Ovarian angiosarcomas are rare, and probably arise from carcinosarcomas, teratomas or the rich ovarian vasculature. To date, only two small case series have been published, one with four cases and the other with seven. CASE PRESENTATION: A 41-year-old Saudi woman presented to our gynecological clinic with abnormal vaginal bleeding. The initial clinical diagnosis was left ovarian cyst...
2014: Journal of Medical Case Reports
Jayson Wang, Cyril Fisher, Khin Thway
Primary de novo angiosarcoma of the breast is an uncommon, aggressive neoplasm. Here, we present a case of a young woman who initially developed primary angiosarcoma of the breast, and subsequently angiosarcoma of the ovary during pregnancy two years later. Only two confirmed primary angiosarcomas of the breast metastasizing specifically to the ovary have been described in the literature. However, all previous cases had ovarian metastases at presentation or shortly after initial diagnosis. This case is unusual as it occurred after a relatively long interval, and apparently developed during pregnancy...
2013: Case Reports in Oncological Medicine
Cassandra Albertin, Karen A Johnson, Joseph P Connor, Ahmed N Al-Niaimi
► Ovarian angiosarcomas are rare and clinically aggressive neoplasms. ► In addition to surgery, taxol is the most studied adjuvant chemotherapy. ► Anti-angiogenic therapies can be considered as an option.
2013: Gynecologic Oncology Case Reports
Stephanie H Guseh, Leslie S Bradford, Lida P Hariri, John O Schorge
No abstract text is available yet for this article.
2012: Gynecologic Oncology Case Reports
Anita Chudecka-Głaz, Janusz Menkiszak, Sławomir Kuźniak, Magdalena Lewandowska, Mirosław Burak, Anna Walecka
Angiosarcoma is a rare form of sarcoma which may be either a primary tumor or it may result from previous irradiation because of another tumor. In this paper, we present a case of a female patient diagnosed as having peritoneal disseminated angiosarcoma 20 years after ovarian cancer treatment (surgery, chemotherapy and radiotherapy). The case was very atypical because of an extremely rare peritoneal location and disseminated nature of the changes. Based on the initial histological picture, poorly differentiated cancer metastasis was diagnosed, suggesting a recurrence of the ovarian cancer that had been diagnosed earlier...
2014: Gynecologic and Obstetric Investigation
Arnold-Jan Kruse, Simone Sep, Brigitte F M Slangen, Nathalie M Vandevijver, Toon Van Gorp, Roy F Kruitwagen, Koen K Van de Vijver
OBJECTIVE: Angiosarcomas are aggressive, malignant soft tissue neoplasms of endothelial origin and occur rarely in the female genital tract. There is lack of consensus on risk factors for poor outcome and optimal treatment. To this end, we performed a clinicopathologic review and survival analysis. METHODS: We report a case of a woman with an angiosarcoma of the vagina. Published English literature was reviewed for angiosarcomas of the vulva, vagina, uterus, and ovary...
January 2014: International Journal of Gynecological Cancer
Michael J Kluk, Todd Ashworth, Hongfang Wang, Birgit Knoechel, Emily F Mason, Elizabeth A Morgan, David Dorfman, Geraldine Pinkus, Oliver Weigert, Jason L Hornick, Lucian R Chirieac, Michelle Hirsch, David J Oh, Andrew P South, Irene M Leigh, Celine Pourreyron, Andrew J Cassidy, Daniel J Deangelo, David M Weinstock, Ian E Krop, Deborah Dillon, Jane E Brock, Alexander J F Lazar, Myron Peto, Raymond J Cho, Alexander Stoeck, Brian B Haines, Sriram Sathayanrayanan, Scott Rodig, Jon C Aster
Fixed, paraffin-embedded (FPE) tissues are a potentially rich resource for studying the role of NOTCH1 in cancer and other pathologies, but tests that reliably detect activated NOTCH1 (NICD1) in FPE samples have been lacking. Here, we bridge this gap by developing an immunohistochemical (IHC) stain that detects a neoepitope created by the proteolytic cleavage event that activates NOTCH1. Following validation using xenografted cancers and normal tissues with known patterns of NOTCH1 activation, we applied this test to tumors linked to dysregulated Notch signaling by mutational studies...
2013: PloS One
Kurtis D Davies, Robert C Doebele
Genetic alterations that lead to constitutive activation of kinases are frequently observed in cancer. In many cases, the growth and survival of tumor cells rely upon an activated kinase such that inhibition of its activity is an effective anticancer therapy. ROS1 is a receptor tyrosine kinase that has recently been shown to undergo genetic rearrangements in a variety of human cancers, including glioblastoma, non-small cell lung cancer (NSCLC), cholangiocarcinoma, ovarian cancer, gastric adenocarcinoma, colorectal cancer, inflammatory myofibroblastic tumor, angiosarcoma, and epithelioid hemangioendothelioma...
August 1, 2013: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Eleonora Savitchi, Sumati Rao
Malignant transformation of a mature ovarian teratoma is a rare occurrence predominantly in the postmenopausal period. All histologic types can be seen; however, squamous cell carcinoma accounts for over 75% of cases. Sarcomatous transformation is much more uncommon, with cases of angiosarcoma, rhabdomyosarcoma, leiomyosarcoma and liposarcoma arising in a mature ovarian teratoma described in literature. We report a case of squamous cell carcinoma and pleomorphic sarcoma arising in a mature cystic teratoma of the ovary in a 58-year-old woman...
September 2012: International Journal of Gynecological Pathology
Hiroyuki Takahashi, Pattama Chaopotong, Sabine Kajita, Miki Hashimura, Hitoshi Yamazaki, Makoto Saegusa
Malignant transformation of a mature teratoma in the ovary is a rare event, with an approximate rate of only 1-2%. Here, we report an ovarian tumor with a unique combination of epithelial and non-epithelial malignant components, including mature teratoma elements. A 59 year-old postmenopusal woman underwent total hysterectomy and bilateral salpingo-oophorectomy to remove a huge solid mass of the right ovary. The ovarian tumor was 16 × 12 × 4.5 cm in dimensions, composed of red-brown and greyish-white tissue with several cystic areas...
August 2012: Pathology International
Jorge Villaran, Arturo Loaiza-Bonilla, Carlos Parra-Herran, Andre Pinto
No abstract text is available yet for this article.
January 2013: Pathology Oncology Research: POR
Oleksandr N Kryvenko, Nilesh S Gupta, Frederick A Meier, Min W Lee, Jonathan I Epstein
We describe 3 ovarian and 5 renal anastomosing hemangiomas. One manifested with polycythemia, others were incidental; none recurred. The mean patient age was 58 years. Three hemangiomas developed in end-stage renal disease. Tumors were well-demarcated, mahogany brown, spongy lesions measuring 0.1 to 5 cm. Tortuous large vessels fed and drained tightly packed anastomosing sinusoidal capillary channels. Four hemangiomas exhibited lobular architecture, central edema/hyalinization, and intravascular growth. Five cases had thrombosis, hemorrhage, and hemosiderin...
September 2011: American Journal of Clinical Pathology
Hans Bösmüller, Christine Gruber, Sophie Haitchi-Petnehazy, Dietmar Wagner, Gerald Webersinke, Steffen Hauptmann
Primary angiosarcoma of the ovary (AS) is a rare entity with only 31 reported cases. The majority are pure angiosarcomas, the remainder are associated either with teratomas or conventional epithelial tumors. More than 50% of ovarian AS are disseminated at the time of diagnosis, the minority is detected in stage I. The prognosis of ovarian angiosarcoma in general is poor. Most reports refer to younger individuals, aged from 7 to 46 years, and only 2 case reports could be found for patients older than 64 years...
2011: Diagnostic Pathology
Ermina Iljazović, Snježana Tomić, Jasminka Mustedanagić-Mujanović, Zinaida Karasalihović, Majda Kuljanin, Zlatan Fatušić, Elvira Konjić, Edin Husarić, Amila Latifagić, Lejla Arnautalić
Sarcomas of the female genital tract in general are rare and ovarian sarcomas comprise less than 1% of ovarian malignancies. In the literature there are 15 reported angiosarcomas of patients 21 year old and younger with no one originated in the ovary. We report a case of ovarian angiosarcoma in an 11 year old girl, presented with left side hip pain. MRI of abdomen and pelvis confirmed expansive solid and cystic mass occupied both ovaries. Imunohistochemistry staining was performed, CD34, Factor VIII, CD31, in order to confirm the diagnosis...
May 2011: Bosnian Journal of Basic Medical Sciences
M Khasraw, A Holodny, S A Goldlust, L M DeAngelis
BACKGROUND: Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor approved for recurrent glioblastoma (GBM), metastatic breast, colorectal and non-small-cell lung cancers (NSCLC). There has been a potentially increased risk of intracranial hemorrhage (ICH) in patients receiving bevacizumab. METHODS: We retrospectively identified patients with ICH who received bevacizumab between 1 January 2001 and 10 January 2009. RESULTS: We identified 1024 patients with ICH, 4191 patients who received bevacizumab and 12 (0...
February 2012: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"